Why do Mounjaro and Wegovy start low?
Escalation means starting at the labelled dose, staying there for the required interval, then letting the clinician decide whether the next step fits. The starting dose is not intended to deliver the maximum first-month effect. It introduces the medicine's effects on appetite and gastric movement while tolerability is observed. Semaglutide and tirzepatide labels use escalation to reduce gastrointestinal reactions; nausea, vomiting, diarrhoea and constipation occur most often during initiation or dose increases [1, 2, 3, 4, 5].
“Every four weeks” is the minimum interval, not an automatic increase. If symptoms persist, intake becomes difficult, or another medicine needs adjustment, the clinician may hold the dose longer. Skipping a step or shortening the interval increases exposure before the digestive system adapts. No nausea is not permission to accelerate and does not prove that a higher dose is needed [1, 2, 3, 6].
Keep ingredient, brand and authorised use distinct. Wegovy contains semaglutide; Mounjaro and Zepbound contain tirzepatide, but each has its own label, indications and presentations. A shared ingredient does not make pens or instructions interchangeable. This article covers weekly schedules, not eligibility or comparative results; the general GLP-1 guide provides that context. Your clinician chooses the product and dose [1, 2, 3, 7, 8].
The weekly Wegovy injection schedule
The current US Wegovy injection label starts at 0.25 mg weekly in weeks 1–4, then 0.5 mg in weeks 5–8, 1 mg in weeks 9–12 and 1.7 mg in weeks 13–16. From week 17, maintenance is 1.7 or 2.4 mg weekly, selected by response and tolerability. If a step is not tolerated, the clinician may delay escalation for four weeks. Do not make that change independently [1].
This schedule applies to Wegovy injection. Do not transfer a dose from Ozempic or another semaglutide product and assume that its numbers, pen or use are identical. Concentrations, pen designs, available doses and authorised indications can differ despite a shared ingredient. The 0.25 mg dose is an introduction step; no immediate appetite or scale change is not failure or a reason to jump to maintenance [1, 9].
Before each step, the clinician asks about vomiting, adequate food and fluid, constipation or diarrhoea, dizziness or low glucose with other diabetes medicines, and benefit versus harm. The answers may support continuing, delaying or reassessing. An online chart is not a personal prescription, and 2.4 mg is not a target everyone must reach [1, 4, 8, 9].
Tirzepatide escalation: Mounjaro and Zepbound
The current Mounjaro label starts tirzepatide at 2.5 mg weekly for four weeks, then 5 mg. If more control is needed, later increases are 2.5 mg after at least four weeks at the current dose: 7.5, 10, 12.5 and 15 mg for adults. The 2.5 mg dose starts treatment rather than providing glycaemic control; the adult maximum is 15 mg weekly. The clinician decides whether any later increase is needed [2].
Zepbound contains tirzepatide but has its own label for chronic weight management and specified related conditions. It also starts at 2.5 mg weekly for four weeks, then 5 mg, with later 2.5 mg increases after at least four weeks. Weight-management maintenance doses are 5, 10 or 15 mg, selected by response and tolerability; 15 mg is the maximum. The 7.5 and 12.5 mg steps are not maintenance targets, and a shared ingredient does not permit independent brand switching [3].
Tirzepatide studies used a low start and spaced increases to improve gastrointestinal tolerability. Events appeared mainly during escalation and often diminished over time, but not everyone tolerates every step. A lower dose may deliver the agreed benefit, while a higher dose may cause troublesome effects. The clinician weighs benefit, tolerability, health conditions and concurrent medicines; the highest number is not compulsory [3, 5, 6, 10].
Missed doses: Wegovy and tirzepatide use different rules
For one missed Wegovy injection, check the next dose. If it is more than two days away, take the missed dose promptly; if less than two days away, skip it and return to the usual day. Do not combine doses. After two or more consecutive missed doses, the current label directs re-escalation at a lower dose to reduce gastrointestinal reactions. Contact the prescriber instead of resuming a high dose [1, 9].
For Mounjaro or Zepbound, take a missed dose within four days, or 96 hours. After that, skip it and take the next dose on the regular day. Both tirzepatide labels (Mounjaro and Zepbound) require at least 72 hours between doses when changing the weekly day. This boundary does not permit routine closer dosing or more than one dose weekly [2, 3, 10].
For a longer interruption, tell the clinician the last tolerated dose, how many were missed and why treatment stopped. Returning after vomiting, dehydration, surgery, acute illness or poor intake differs from forgetting one day. Wegovy explicitly addresses re-escalation after multiple missed doses; tirzepatide labels give a single-missed-dose rule and do not authorise restarting high after weeks away. Advice for another dose or product does not apply [1, 2, 3].
Symptoms after an increase: when to monitor and when to seek help
Nausea, diarrhoea, vomiting, constipation and abdominal pain are common, particularly during escalation. In semaglutide and tirzepatide trials, most gastrointestinal events were mild or moderate and temporary, but some participants stopped treatment. Do not dismiss symptoms or treat vomiting as proof that the medicine is “working.” Inability to drink or eat is not a treatment goal [4, 5, 8].
For mild symptoms, record their timing against doses and meals. Eat smaller meals slowly, stop at fullness, limit rich food if it worsens nausea, and take appropriate fluids. Do not add anti-nausea medicine, laxatives or supplements because someone else did. Constipation with severe pain, swelling or vomiting needs assessment. If symptoms persist at the next escalation date, contact the clinician before increasing. The linked Q&A covers daily measures [4, 5, 8].
Seek urgent assessment for severe persistent abdominal pain, especially into the back; vomiting that prevents fluids; very little urine, severe dizziness or fainting; or facial or tongue swelling with breathing difficulty. Strong right-upper abdominal pain with fever or yellowing also needs urgent care. With insulin or another medicine that can cause hypoglycaemia, sweating, shaking or confusion requires the agreed low-glucose plan and help according to severity. Contact the treating team or emergency care; this article cannot choose the next dose [1, 2, 3, 8, 9, 10].
Why click-counting or pen splitting is not safe dosing
Social-media charts may suggest counting pen “clicks,” withdrawing medicine with a syringe or using apparent remnants. Do not. Measure only as instructed for that exact product and prescribed. US Wegovy pens in the FDA alert deliver a preset dose; they are not partial-dose calculators. Pens differ by product and market, so clicks and appearance are not standard units transferable from a video [1, 11].
Risk is greater with compounded or unapproved containers. The FDA documented errors when people measured liquid “units” instead of milligrams; with different concentrations, the same volume can contain a different amount. Some errors required medical care or admission. Unapproved products lack the same premarket review for safety, effectiveness and quality. Never convert mg, mL and syringe units yourself, use an unprescribed device, or obtain unidentified products [11, 12].
If your prescribed dose is unavailable in your pen presentation, do not manufacture it. Photograph the name, strength and pharmacy label without personal details, then ask the prescriber or licensed pharmacist before injection. Do not use a package with unexpected liquid, an incomplete label or unclear instructions until verified. Dosing errors can cause severe vomiting, dehydration or other harm, especially when they create an unplanned jump [11, 12].
The appropriate dose is not necessarily the highest dose
An increase needs both clinical benefit and acceptable tolerability; the scale alone cannot decide. Record injection day and dose, hunger, fullness, nausea or vomiting, bowel pattern, fluids, dizziness, and requested glucose readings. Add any new medicine, operation or illness. A two- or four-week record is more useful than saying a dose “stopped working” after one hungry day [1, 2, 3, 7].
Do not increase because someone else lost faster or alter a dose because of a post. The clinician may delay escalation, choose a lower maintenance dose, or reconsider treatment if benefit is limited. Some tirzepatide strengths are escalation steps and others are maintenance doses depending on product and indication; Wegovy injection offers two maintenance options. Not every path ends at the highest number [1, 2, 3].
Dose is part of a long-term plan, not a monthly race. Structured eating, fluids, protein, micronutrients, suitable movement and health-condition follow-up remain important. The linked article covers continuation, stopping and regain. Any interruption, restart or product switch needs a prescriber-led plan, even after a related medicine [7, 8].
Your next step before the next dose
Before the appointment, prepare the product name, strength, last-dose date, number missed, and symptoms with their duration. List diabetes medicines, insulin, oral medicines and supplements. Ask whether the dose is for initiation or maintenance, why an increase is needed now, and when symptoms require a call or emergency care. The first-visit guide helps organise your history, medicines and goals without starting independently [1, 2, 3, 7].
When starting, escalating or returning after interruption, the medical team at La Rose can review the clinical picture during a consultation, with branches in Maadi and Fifth Settlement, New Cairo. This does not promise that a medicine suits you or replace emergency care. Bring the original pen or package, medicine list and symptom record. Do not inject an unclear dose until the clinician or licensed pharmacist checks it [7, 8, 11, 12]. For non-urgent concerns, you can book a consultation with the medical team.
